trilaciclib sold brand name cosela medication used reduce frequency chemotherapyinduced bone marrow common side effects include fatigue low levels calcium potassium phosphate increased levels enzyme called aspartate aminotransferase headache infection lungs trilaciclib may help protect bone marrow cells damage caused chemotherapy inhibiting cyclindependent kinase type trilaciclib first therapy class approved medical use united states february us food drug administration considers firstinclass chemotherapy drugs designed kill cancer cells damage normal tissues bone marrow particularly susceptible chemotherapy bone marrow makes red blood cells white blood cells platelets small fragments blood transport oxygen fight infection stop damaged bone marrow produces fewer cells leading fatigue increased risk infection bleeding among trilaciclib may help protect normal bone marrow cells harmful effects trilaciclib indicated reduce frequency chemotherapyinduced bone marrow suppression adults receiving certain types chemotherapy extensivestage cancer spread beyond lungs small cell lung effectiveness trilaciclib evaluated three randomized doubleblind placebocontrolled studies participants extensivestage small cell lung combined studies randomly assigned participants receive either infusion trilaciclib veins placebo studies compared two groups proportion participants severe neutropenia low count white blood cells called neutrophils duration severe neutropenia first cycle three studies participants received trilaciclib lower chance severe neutropenia compared participants received among severe neutropenia participants received trilaciclib average shorter time participants received us food drug administration fda granted application trilaciclib priority review breakthrough therapy fda granted approval cosela therapeutics article incorporates public domain material united states department health human services pharmacologyrelated article stub help wikipedia expanding ithttpsenwikipediaorgwikitrilaciclib